https://www.thebodypro.com/category/hiv-treatments-in-development
HIV Treatment Strategies

HIV Treatments in Development

The Latest

Immune-Based Therapy Canakinumab Reduces Inflammatory Markers in HIV-Positive People on ART Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Immune-Based Therapy Canakinumab Reduces Inflammatory Markers in HIV-Positive People on ART

"We believe this is one of the first immune-based therapies to show a very profound reduction in inflammatory markers in the setting of treated HIV," Priscilla Hsue, M.D. states.

Increased Risk of IRIS With Integrase Inhibitors Reported in Two Studies Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Increased Risk of IRIS With Integrase Inhibitors Reported in Two Studies

Two cohort studies showed a higher risk of IRIS with integrase inhibitor-based ART than with other regimens.

Dock and Block: Scientists Develop Technique That Makes Cells Resistant to HIV Img

Dock and Block: Scientists Develop Technique That Makes Cells Resistant to HIV

Scientists at The Scripps Research Institute (TSRI) have discovered a way of creating HIV- resistant cells by using antibodies to block HIV directly on the cell surface.

Bictegravir Matches Dolutegravir in HIV Control and Safety Img

Bictegravir Matches Dolutegravir in HIV Control and Safety

Combined with tenofovir alafenamide/emtricitabine (TAF/FTC, Descovy), the investigational HIV integrase inhibitor bictegravir matched the licensed integrase inhibitor dolutegravir (Tivicay, DTG) in viral suppression and safety, according to phase-2 s...

Bictegravir -- An Emerging Integrase Inhibitor Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Bictegravir -- An Emerging Integrase Inhibitor

Bictegravir-containing regimens performed well over 48 weeks, with more than 90% of participants achieving a viral load less than 50 copies/mL.

A New Nuke in the Works -- GS-9131 Img
CROI (Conference on Retroviruses and Opportunistic Infections)

A New Nuke in the Works -- GS-9131

The new nucleoside analogue GS-9131 may be useful as part of regimens for people who have strains of drug-resistant HIV.

Doravirine versus Darunavir Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Doravirine versus Darunavir

A recent clinical trial found that doravirine was roughly equivalent in potency to darunavir-based regimens.

New Drugs, New Hope and Possible Timelines Img
CROI (Conference on Retroviruses and Opportunistic Infections)

New Drugs, New Hope and Possible Timelines

At the recent Conference on Retroviruses and Opportunistic Infections, researchers presented data about 5 new anti-HIV compounds in development.

Do Integrase Inhibitors Affect Testosterone Levels in Men? Img
Endocrine/Sexual Dysfunction

Do Integrase Inhibitors Affect Testosterone Levels in Men?

In a small cross-sectional study researchers found a link between the use of integrase inhibitors and the presence of low testosterone, but they may have inadvertently arrived at this conclusion.